Brace yourselves for a potential upsurge in action – both in price and probably elsewhere - in the dipeptidyl peptidase-4 (DPP-4) inhibitor segment in India.
Brace yourselves for a potential upsurge in action – both in price and probably elsewhere - in the dipeptidyl peptidase-4 (DPP-4) inhibitor segment in India.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.
